VRCA Earnings Date: Nov 13, 2026 (Estimated) — Verrica Pharmaceuticals Inc.
NASDAQ
Updated
When is VRCA's next earnings date?
Verrica Pharmaceuticals Inc. (VRCA) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.45 on revenue of $6.2M.
How did VRCA do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Verrica Pharmaceuticals Inc. posted EPS of -$0.48 versus the -$0.39 estimate, a miss of 0.0%. Revenue was $5.9M against a $5.7M estimate. The stock's 1-day post-earnings move was -5.2%.
How much does VRCA stock move after earnings?
VRCA beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.1% (up or down) in the day after earnings.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.39 | -0.48 | +0.00% | $5.9M | ❌ Miss | -5.22% | -9.33% | -1.12% |
| 2026-05-12 | Q1 2026 | -0.59 | -0.41 | +30.51% | $5.0M | ✅ Beat | +3.08% | -21.82% | -15.73% |
| 2026-03-11 | Q4 2025 | -0.56 | -0.51 | +8.93% | $5.1M | ✅ Beat | +4.68% | +5.52% | -2.51% |
| 2025-11-14 | Q3 2025 | -0.97 | 0.13 | +113.40% | $14.3M | ✅ Beat | +1.55% | +3.88% | +95.35% |
| 2025-08-12 | Q2 2025 | -0.78 | 0.25 | +132.05% | $12.7M | ✅ Beat | -3.37% | -11.29% | -27.57% |
| 2025-03-11 | Q4 2024 | -0.24 | -0.18 | +25.00% | $344,000 | ✅ Beat | -7.56% | +0.28% | -28.59% |
| 2024-11-04 | Q3 2024 | -0.37 | -0.43 | -16.22% | $-1.8M | ❌ Miss | -6.54% | -45.76% | -22.88% |
| 2024-08-14 | Q2 2024 | -0.42 | -0.31 | +26.19% | $5.2M | ✅ Beat | -40.80% | -46.30% | -63.19% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $5.9M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 86.4% | $5.1M | +12.3% | — | $315K | $3.4M | $4.5M |
| License And Collaboration Revenue | 13.6% | $800K | -90.2% | — | — | — | $8.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.